Apogee Therapeutics's top three insider shareholders as of June 18, 2026 are Nimish P Shah (Director, 1.75Mn shares), Carl Dambkowski (Chief Medical Officer, 208.40K shares), Jane Henderson (Chief Financial Officer, 175.37K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Jane Henderson | Chief Financial Officer | 175,371 | 0 | 17 Apr, 2026 |
| Nimish P Shah | - | 0 | 1,750,000 | 17 Jul, 2023 |
| Mark C. Mckenna | - | 20,000 | 0 | 16 Dec, 2024 |
| Carl Dambkowski | Chief Medical Officer | 208,398 | 0 | 03 Apr, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 16 Apr, 2026 | Jane Henderson | Common Stock | D | 2,000 | $90.00 | 175,371 | D | S |
| 01 Apr, 2026 | Jane Henderson | Common Stock | D | 900 | $84.46 | 178,471 | D | S |
| 01 Apr, 2026 | Carl Dambkowski | Common Stock | A | 4,125 | $22.86 | 213,898 | D | M |
| 01 Apr, 2026 | Carl Dambkowski | Common Stock | D | 2,698 | $84.31 | 211,200 | D | S |
| 01 Apr, 2026 | Jane Henderson | Common Stock | D | 1,100 | $85.46 | 177,371 | D | S |
| 01 Apr, 2026 | Carl Dambkowski | Common Stock | D | 2,702 | $85.33 | 208,498 | D | S |
| 01 Apr, 2026 | Carl Dambkowski | Common Stock | D | 100 | $85.89 | 208,398 | D | S |
| 01 Apr, 2026 | Carl Dambkowski | Stock Option (Right to Buy) | D | 4,125 | $0.00 | 127,165 | D | M |
| 25 Mar, 2026 | Jane Henderson | Common Stock | D | 2,000 | $85.00 | 179,371 | D | S |
| 04 Mar, 2026 | Carl Dambkowski | Common Stock | A | 4,125 | $22.86 | 215,273 | D | M |
| 04 Mar, 2026 | Carl Dambkowski | Common Stock | D | 3,225 | $70.33 | 212,048 | D | S |
| 04 Mar, 2026 | Carl Dambkowski | Common Stock | D | 2,075 | $71.98 | 209,973 | D | S |
| 04 Mar, 2026 | Carl Dambkowski | Common Stock | D | 200 | $73.26 | 209,773 | D | S |
| 04 Mar, 2026 | Carl Dambkowski | Stock Option (Right to Buy) | D | 4,125 | $0.00 | 131,290 | D | M |
| 02 Mar, 2026 | Jane Henderson | Common Stock | D | 300 | $68.27 | 183,071 | D | S |
| 02 Mar, 2026 | Jane Henderson | Common Stock | D | 300 | $69.43 | 182,771 | D | S |
| 02 Mar, 2026 | Jane Henderson | Common Stock | D | 994 | $70.45 | 181,777 | D | S |
| 02 Mar, 2026 | Jane Henderson | Common Stock | D | 406 | $71.66 | 181,371 | D | S |
| 02 Feb, 2026 | Jane Henderson | Common Stock | D | 792 | $65.21 | 184,579 | D | S |
| 04 Feb, 2026 | Carl Dambkowski | Common Stock | A | 4,125 | $22.86 | 216,648 | D | M |